Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home
TrialNet News and Events
Type 1 Diabetes - TrialNet e-news - Spring 2013


Teplizumab continues to gain momentum for slowing progression of type 1 diabetes
Results of a type 1 diabetes clinical trial conducted by the Immune Tolerance Network are in, and future prospects look good for the drug teplizumab. 

In the two year long, phase 2 trial, teplizumab helped stop advancement of the disease in its earliest stages in about half of the 53 participants, most less than 14 years old, as reported in the journal Diabetes. Benefitting most were those who still had relatively good control of their blood sugar levels with only a moderate need for insulin injections. With teplizumab, they were able to maintain their level of insulin production for the full two years.

Led by Kevan Herold, M.D., Professor of Immunobiology and Deputy Director for Translational Science at Yale, the study is of special interest to TrialNet, since Dr. Herold is also leading a study for TrialNet using the same drug. Go


LIFT study offers long-term follow-up
Nine-year-old Sean Lally and fourteen-year-old Raquel Flaksman were already both veterans of TrialNet research studies when they joined the LIFT (Long-Term Investigative Follow-Up in TrialNet) Study. As LIFT Study participants, TrialNet is monitoring their progress, including such factors as disease status, general health, insulin requirements, and long term effects of experimental treatments.

LIFT studies are available nationwide for:

  1. Participants who developed diabetes while participating in either the Pathway to Prevention Study or a prevention study, OR
  2. Participants from new onset studies that have ended. Go

Ryan Reed

NASCAR Driver Ryan Reed's parents join the race to beat type 1 diabetes—encourage other parents to get screened!
When NASCAR Driver Ryan Reed was diagnosed with type 1 diabetes in 2011 at age 17, he was told he would never be able to race again. After dealing with all the normal feelings that come with such a prognosis, Ryan and his parents got busy.

Ryan found Dr. Anne Peters, a renowned endocrinologist with the University of Southern California, who had worked with Charlie Kimball, the first licensed driver with diabetes to win a race in the IZOD IndyCar Series. Dr. Peters was willing to work with Ryan to come up with a plan to get healthy before returning to racing. "It took Ryan 6 months to not only get healthy but to get his mind around the disease," explains his mother, Karla. Go


Pathway to Prevention Study (formerly the Natural History Study of the Development of Type 1 Diabetes):
Screening and observing relatives of people with type 1 diabetes to learn more about how the disease occurs.

Oral Insulin for Prevention of Type 1 Diabetes Study:
Testing whether a daily oral insulin capsule can prevent or delay type 1 diabetes in at-risk relatives of people with the disease.

Teplizumab (Anti-CD3) Prevention Study:
Testing whether the drug teplizumab can stop or slow down the autoimmune reaction that is destroying beta cells in people who are at high risk of developing type 1 diabetes.

Abatacept Prevention Study:
Testing whether abatacept, a medication that has shown promise in preserving insulin production in people newly diagnosed with type 1 diabetes, can help delay or prevent onset of the disease in people at increased risk.

LIFT (Long-Term Investigative Follow-Up in TrialNet) Study:
Monitoring the long-term progress of participants from the Pathway to Prevention Study or a prevention study who have developed type 1 diabetes; or participants from new onset studies that have ended.



TrialNet pays tribute to Dr. George Eisenbarth
In observance of World Diabetes Day (November 14) and American Diabetes Month (November), TrialNet pays tribute to Dr. George Eisenbarth, a great American scientist who advanced type 1 diabetes research on a worldwide level. Passing away last November after a long struggle with pancreatic cancer, Dr. Eisenbarth's studies helped define the progressive autoimmune nature of the disease, leading to new approaches in treatment and prevention. Go


November is American Diabetes Month
Diabetes doesn't stop. It is 24/7, 365 days a year. During American Diabetes Month 2013, the American Diabetes Association (ADA) encourages Americans to share A Day in the Life of Diabetes by uploading a personal image to their Facebook mosaic that shows what the daily life of diabetes means to them.

NASCAR Driver Ryan Reed's race car will be wrapped with photos from the mosaic and will be featured in his November 9 race in Phoenix, AZ.

Learn how you can submit your personal image and story during American Diabetes Month by visiting ADA at

World Diabetes Day

November 14 is World Diabetes Day
World Diabetes Day was created in 1991 by the International Diabetes Federation and the World Health Organization in response to growing concerns about the escalating health threat that diabetes now poses. Each year, the campaign features a theme to address issues facing the global diabetes community. While the themed campaigns last the whole year, the day itself is celebrated on November 14, to mark the birthday of Frederick Banting who, along with Charles Best, first conceived the idea, which led to the discovery of insulin in 1922. This year's theme is Diabetes Education and Prevention. Go

TrialNet risk screening available virtually anywhere

TrialNet risk screening is available at more than 200 locations throughout North America or anywhere in the United States via mail. You can find a TrialNet screening location by using our online referral tool. To request a test kit by mail, go to www.Pathway2Prevention.org and complete the informed consent process, or contact one of our clinical centers listed here. The test kit can be taken to a local medical lab to collect a blood sample for analysis by TrialNet’s lab. Risk screening is available at no charge to those who are:

  • age 45 and younger who have a parent, sibling or child with type 1 diabetes, or
  • age 20 and younger who have a niece, nephew, aunt, uncle, grandparent, half-sibling, or cousin with type 1 diabetes.

Facebook Visit us on Facebook You Tube TrialNet YouTube Channel Twitter Follow us on Twitter

Join TrialNet in the fight against type 1 diabetes!

Here's how YOU can help:

  • If you have a relative with type 1 diabetes, find out if you are eligible for screening; if you are, get involved and get your family screened
  • Forward TrialNet E-News to family members and friends who might be interested
  • Tell your TrialNet Story by creating a video for TrialNet’s YouTube channel
  • Share this information on your MySpace or Facebook page
  • Follow TrialNet on Facebook and Twitter